Alogliptin Treatment Improves Nerve and Vascular Function in Diabetic Rats
Author Information
Author(s): Eric P. Davidson, Lawrence J. Coppey, Brian Dake, Mark A. Yorek
Primary Institution: University of Iowa
Hypothesis
Does dipeptidyl peptidase IV (DPP-IV) inhibition improve vascular and neural complications in streptozotocin-induced diabetic rats?
Conclusion
Alogliptin treatment improved some neural and vascular complications in diabetic rats but did not enhance intraepidermal nerve fiber density.
Supporting Evidence
- Diabetes caused a slowing of motor and sensory nerve conduction velocity.
- Treatment with Alogliptin significantly improved motor nerve conduction velocity.
- Vascular relaxation to calcitonin gene-related peptide was significantly improved with treatment.
Takeaway
This study found that a medicine called Alogliptin can help some problems with nerves and blood vessels in diabetic rats, but it doesn't help with nerve fiber loss.
Methodology
Diabetic rats were treated with Alogliptin for 12 weeks after 4 weeks of untreated diabetes, and various nerve and vascular functions were measured.
Potential Biases
Potential bias due to the lack of blinding in some assessments.
Limitations
The study did not measure the activity of GLP-1, and the treatment period may not have been long enough to observe full nerve regeneration.
Participant Demographics
Male Sprague-Dawley rats, 12 weeks of age.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website